Umbilical Cord Subepithelial Stem Cells for Allogenic Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The clinical translation of various cell types for human and animal therapeutic applications is limited due to allogenic issues, hindering their widespread use in treating conditions such as COPD, diabetes, ischemia, osteoarthritis, and autoimmune disorders.
Innovation Solution
The development of isolated cells from the subepithelial layer of mammalian umbilical cord tissue, expressing specific markers and lacking others, capable of self-renewal and culture expansion, which can be differentiated into adipocytes, chondrocytes, osteocytes, and cardiomyocytes, and used to treat medical conditions through direct administration or exosome delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If allogenic cell populations are used for therapeutic applications, then treatment options are limited, but immune rejection occurs
Solution Approach 1:
The patent uses umbilical cord tissue as an intermediary source that naturally lacks HLA-DR expression, serving as a bridge between allogenic cell availability and immune compatibility. This intermediary source provides cells that can be used therapeutically without triggering strong immune rejection responses.
Solution Approach 2:
The patent changes the immunological parameters of the cells by selecting for HLA-DR negative cells from umbilical cord tissue. This parameter change (HLA-DR expression status) fundamentally alters the immune compatibility profile of the cells, allowing broader therapeutic use without immune rejection.
2Quantity of substance
If stem cells are cultured and expanded, then cell quantity increases, but culture conditions and time requirements increase
Solution Approach 1:
The patent performs preliminary actions by establishing optimized culture conditions and protocols before clinical application. The subepithelial layer cells are pre-characterized and pre-tested for their culture requirements, allowing for rapid expansion when needed without extensive optimization time during treatment.
Solution Approach 2:
The subepithelial layer cells exhibit self-renewal capabilities and can be expanded in culture using their intrinsic properties. The cells serve themselves by maintaining their stem cell characteristics and differentiation potential throughout culture expansion, reducing the need for complex external intervention.
3Manufacturing precision
If specific cell markers are used to identify stem cells, then cell purity increases, but identification complexity increases
Solution Approach 1:
The patent applies local quality by focusing on specific marker expression patterns (CD29+, CD73+, CD90+, CD166+, SSEA4+, CD9+, CD44+, CD146+, CD105+) and negative markers (CD45-, CD34-, CD14-, CD79-, CD106-, CD86-, CD80-, CD19-, CD117-, Stro-1-, HLA-DR-). This localized marker profile approach simplifies identification compared to comprehensive stem cell characterization.
Data Source
AI summary
Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.